Stocks and Investing
Stocks and Investing
Mon, March 11, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Raghuram Selvaraju Maintained (AQST) at Strong Buy with Increased Target to $7 on, Mar 11th, 2024
Raghuram Selvaraju of HC Wainwright & Co., Maintained "Aquestive Therapeutics, Inc." (AQST) at Strong Buy with Increased Target from $6 to $7 on, Mar 11th, 2024.
Raghuram has made no other calls on AQST in the last 4 months.
There are 2 other peers that have a rating on AQST. Out of the 2 peers that are also analyzing AQST, 0 agree with Raghuram's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Raghuram
- Andreas Argyrides of "Wedbush" Maintained at Buy with Increased Target to $9 on, Thursday, March 7th, 2024
- Thomas Flaten of "Lake Street" Maintained at Strong Buy with Increased Target to $8 on, Thursday, March 7th, 2024
Contributing Sources